FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
🩺 Protocol Summary
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms
Primary Research Facility: Anaheim Clinical Trials, LLC (Anaheim, California)
📋 Preliminary Self-Screener
0 of 3 AnsweredAnswer all 3 basic criteria below to see your preliminary screening result:
📍 Primary Site Map
Site: Anaheim Clinical Trials, LLC — Anaheim, California
📍 All Participating Trial Locations (5 Sites)
Multi-Center TrialThis protocol is enrolling participants across multiple clinical centers:
📄 Print Doctor Discussion Sheet
Preview and print a 1-page summary with 5 tailored questions for your physician.
💰 Clinical Trial Costs & Insurance Coverage
Coverage for clinical trial participation varies depending on your health insurance policy, state legislation, and whether specific procedures are investigational research or routine medical care. Under federal law (Affordable Care Act § 2709), health insurers generally cannot drop coverage or refuse to pay for routine patient care costs incurred in approved clinical trials.
💡 Always ask the study coordinator for the trial's official Informed Consent Form, which outlines all sponsor-funded research items versus procedures billed to your insurance.